Henry Schein (HSIC) Stock Price, News & Analysis

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 1 sell rating, 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HSIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HSIC, but not buy additional shares or sell existing shares.
View HSIC analyst ratings or view top-rated stocks.

11 equities research analysts have issued 1-year price objectives for Henry Schein's shares. Their HSIC share price targets range from $65.00 to $96.00. On average, they predict the company's share price to reach $81.09 in the next twelve months. This suggests a possible upside of 15.5% from the stock's current price.
View analysts price targets for HSIC or view top-rated stocks among Wall Street analysts.

Henry Schein's stock was trading at $75.71 at the beginning of 2024. Since then, HSIC shares have decreased by 7.3% and is now trading at $70.20.
View the best growth stocks for 2024 here.

Henry Schein saw a drop in short interest in March. As of March 31st, there was short interest totaling 5,500,000 shares, a drop of 6.8% from the March 15th total of 5,900,000 shares. Based on an average daily volume of 1,140,000 shares, the short-interest ratio is presently 4.8 days. Currently, 4.3% of the company's shares are sold short.
View Henry Schein's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our HSIC earnings forecast.

Henry Schein will be holding an earnings conference call on Tuesday, May 7th at 10:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Henry Schein, Inc. (NASDAQ:HSIC) released its quarterly earnings results on Tuesday, February, 27th. The company reported $0.66 earnings per share for the quarter, missing analysts' consensus estimates of $0.70 by $0.04. The company earned $3.02 billion during the quarter, compared to analysts' expectations of $3 billion. Henry Schein had a trailing twelve-month return on equity of 14.03% and a net margin of 3.37%. Henry Schein's revenue was down 10.5% compared to the same quarter last year. During the same period last year, the business posted $1.21 EPS.
Read the conference call transcript.

ETFs with the largest weight of Henry Schein (NASDAQ:HSIC) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), American Century Focused Large Cap Value ETF (FLV), Invesco Bloomberg Analyst Rating Improvers ETF (RYJ), Invesco S&P 500 Equal Weight Health Care ETF (RYH), Invesco S&P 500 Equal Weight Health Care ETF (RSPH), First Trust Health Care AlphaDEX Fund (FXH), VictoryShares US Small Mid Cap Value Momentum ETF (USVM) and Arrow Reverse Cap 500 ETF (YPS).

Shares of Henry Schein split before market open on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly issued shares were payable to shareholders after the market closes on Thursday, September 14th 2017. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Henry Schein declared that its Board of Directors has approved a share repurchase plan on Thursday, August 18th 2022, which allows the company to repurchase $400,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to buy up to 4% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's board believes its shares are undervalued.

Henry Schein issued an update on its FY24 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of $5.00 to $5.16 for the period, compared to the consensus estimate of $5.10. The company issued revenue guidance of +8 to +12% yr/yr or $13.326 billion to $13.820 billion, compared to the consensus revenue estimate of $12.93 billion.

451 employees have rated Henry Schein Chief Executive Officer Stanley M. Bergman on Glassdoor.com. Stanley M. Bergman has an approval rating of 94% among the company's employees. This puts Stanley M. Bergman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Henry Schein investors own include Alibaba Group (BABA), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Intel (INTC), NVIDIA (NVDA), QUALCOMM (QCOM), CVS Health (CVS), Micron Technology (MU) and AT&T (T).

Henry Schein's stock is owned by a variety of retail and institutional investors. Top institutional investors include Perpetual Ltd (1.88%), Baker Ellis Asset Management LLC (0.04%), Galibier Capital Management Ltd. (0.04%), Bridge Creek Capital Management LLC (0.03%), Wealth Enhancement Advisory Services LLC (0.03%) and Salem Investment Counselors Inc. (0.03%). Insiders that own company stock include Bradford C Connett, David B Brous Jr, Gerald A Benjamin, James P Breslawski, James P Breslawski, Kurt P Kuehn, Lorelei Mcglynn, Mark E Mlotek, Michael S Ettinger, Philip A Laskawy, Scott Philip Serota, Stanley M Bergman, Steven Paladino and Walter Siegel.
View institutional ownership trends.

Shares of HSIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.